• 1
    Urowitz MB, Gladman DD, Tom BD, Ibanez D, Farewell VT. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 2008; 35: 21528.
  • 2
    Ippolito A, Petri M. An update on mortality in systemic lupus erythematosus. Clin Exp Rheumatol 2008; 26 Suppl: S729.
  • 3
    LaBarbera AR, Miller MM, Ober C, Rebar RW. Autoimmune etiology in premature ovarian failure. Am J Reprod Immunol Microbiol 1988; 16: 11522.
  • 4
    McDermott EM, Powell RJ. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis 1996; 55: 2249.
  • 5
    Alpizar-Rodriguez D, Romero-Diaz J, Cravioto MC, Sanchez-Guerrero J. Prevalence of menopausal symptoms in patients with systemic lupus erythematosus (SLE) [abstract]. Arthritis Rheum 2007; 56 Suppl: S735.
  • 6
    The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17: 24255.
  • 7
    Pines A, Sturdee DW, Birkhauser MH, Schneider HP, Gambacciani M, Panay N, on behalf of the Board of the International Menopause Society. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007; 10: 18194.
  • 8
    Martin KA, Manson JE. Approach to the patient with menopausal symptoms. J Clin Endocrinol Metab 2008; 93: 456775.
  • 9
    Sanchez-Guerrero J, Gonzalez-Perez M, Durand-Carbajal M, Lara-Reyes P, Jimenez-Santana L, Romero-Diaz J, et al. Menopause hormonal therapy in women with systemic lupus erythematosus. Arthritis Rheum 2007; 56: 30709.
  • 10
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 11
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 63040.
  • 12
    Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW) Park City, Utah, July, 2001. Menopause 2001; 8: 4027.
  • 13
    Greene JG. Constructing a standard climacteric scale. Maturitas 2008; 61: 7884.
  • 14
    Travers C, O'Neill SM, King R, Battistutta D, Khoo SK. Greene Climacteric Scale: norms in an Australian population in relation to age and menopausal status. Climacteric 2005; 8: 5662.
  • 15
    Kapur P, Sinha B, Pereira BM. Measuring climacteric symptoms and age at natural menopause in an Indian population using the Greene Climacteric Scale. Menopause 2009; 16: 37884.
  • 16
    Chattha R, Kulkarni R, Nagarathna R, Nagendra HR. Factor analysis of Greene's Climacteric Scale for Indian women. Maturitas 2008; 59: 227.
  • 17
    Derman RJ, Dawood MY, Stone S. Quality of life during sequential hormone replacement therapy: a placebo controlled study. Int J Fertil Menopausal Stud 1995; 40: 738.
  • 18
    Baerug U, Winge T, Nordland G, Faber-Swensson E, Heldaas K, Norling B, et al. Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms? Climacteric 1998; 1: 21928.
  • 19
    Cravioto MC, Larrea F, Delgado NE, Escobar AR, Diaz-Sanchez V, Dominguez J, et al. Pharmacokinetics and pharmacodynamics of 25-mg estradiol implants in postmenopausal Mexican women. Menopause 2001; 8: 35360.
  • 20
    Soares CN, Arsenio H, Joffe H, Bankier B, Cassano P, Petrillo LF, et al. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep and quality of life. Menopause 2006; 13: 7806.
  • 21
    Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 2007; 10: 12031.
  • 22
    Benshushan A, Rojansky N, Chaviv M, Arbel-Alon S, Benmeir A, Imbar T, et al. Climacteric symptoms in women undergoing risk-reducing bilateral salpingo-oophorectomy. Climacteric 2009; 12: 4049.
  • 23
    Kalpakjian CZ, Toussaint LL, Quint EH, Reame NK. Use of a standardized menopause symptom rating scale in a sample of women with physical disabilities. Menopause 2005; 12: 7887.
  • 24
    Avis NE, Brockwell S, Colvin A. A universal menopausal syndrome? Am J Med 2005; 118: 37S46S.
  • 25
    Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health 2006; 96: 122635.
  • 26
    Freeman EW, Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric 2007; 10: 197214.
  • 27
    MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004; 4: CD002978.
  • 28
    Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348: 183954.
  • 29
    Barnabei VM, Cochrane BB, Aragaki AK, Nygaard I, Williams RS, McGovern PG, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 2005; 105: 106373.
  • 30
    Greendale GA, Reboussin BA, Hogan P, Barnabei VM, Shumaker S, Johnson S, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions trial. Obstet Gynecol 1998; 92: 9828.
  • 31
    Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005; 142: 95362.
  • 32
    Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al, for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280; 280: 60513.
  • 33
    Writing Group of the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 32133.
  • 34
    Vickers MR, MacLennan AH, Lawton B, Ford D, Martin J, Meredith SK, et al, for the WISDOM Team. Main morbidities recorded in the Women's International Study of Long Duration Oestrogen After Menopause (WISDOM): a randomized controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007; 335: 23950.
  • 35
    Hagen C, Christensen M, Christiansen C, Stocklund KE, Transbol I. Effects of two years' estrogen-gestagen replacement on climacteric symptoms and gonadotropins in the early postmenopausal period. Acta Obstet Gynaecol Scand 1982; 61: 23741.
  • 36
    Jensen PB, Jensen J, Riis BJ, Rodbro P, Strom V, Christiansen C. Climacteric symptoms after oral and percutaneous hormone replacement therapy. Maturitas 1987; 9: 20715.
  • 37
    Marslew U, Overgaard K, Riis BJ, Christiansen C. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium, and lipid metabolism, climacteric symptoms and bleeding. Obstet Gynecol 1992; 79: 2029.
  • 38
    Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, Mestanza-Peralta M, Lara-Reyes P, Seuc AH, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 253949.
  • 39
    Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Samaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 25508.
  • 40
    Hess EV. Help for menopausal patients with lupus? [editorial]. Ann Intern Med 2005; 142: 10145.
  • 41
    Bermas BL. Menopause management in women with systemic lupus erythematosus. Menopause Manag 2006; 15: 218.